- 2024 Bulletin - First QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin 2024 Q1
- Salix Pharms., Ltd. v. Norwich Pharms. Inc.
- Second QuarterGeneric Launches
- Second QuarterNew ANDA Cases
- Janssen Pharms., Inc. v. Teva Pharms. USA, Inc.
- April 1, 2024Janssen Pharms., Inc. v. Tolmar, Inc.
- Second QuarterANDA Approvals
- March 2024e-Commerce: Pitfalls and Protections
- Endo Ventures Unlimited Co. v. Nexus Pharms. Inc.
- ‘In re Cellect’: How Patent Owners Can Protect Themselves From Obviousness-Type Double Patenting Invalidity Determinations
- Mallinckrodt plc v. Airgas Therapeutics LLC
- How Many Cases Have You Tried to a Verdict?
- March 2024Sellers of a Business: Know Thyself.
- March 2024Unintended Consequences: Don’t Forget the Litigation Risks When Getting a Deal Done
- March 2024Do We Have to Share That Information? Attorney-Client Privilege in the Multi-Entity Cotext
- March 8, 2024UCB, Inc. v. Mylan Techs. Inc.
- March 5, 2024Genentech, Inc. v. Sandoz, Inc.
- March 2024Tony Schrank: Advocating for Justice Beyond the Courtroom
- Janssen Pharms., Inc. v. Tolmar, Inc.
- Endo Par Innovation Co.
v. BPI Labs, LLC - First QuarterANDA Litigation Settlements
- January 2024Entitlement to Priority in the European Patent Office
- Novartis Pharms. Corp. v. Mylan Pharms. Inc.
- Mylan Pharms. Inc. v. Bayer Intellectual Property GmbH
- January 2024Navigating the Legal Landscape: Generative AI and Copyright Law
- 2023 Bulletin - Fourth QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin 2023 Q4
- February 8, 2024Behind the numbers: 2023 patent litigation trends in the Western District of Texas
- January 2024Crack the Code: Evaluating Cyber Claim Exposure
- January 2024Considerations for D&O Insurance in light of the Changing Diversity, Equity, and Inclusion (DEI) Legal Landscape
- January 2024The Weight of Words
- First QuarterNew ANDA Cases
- January 2024The Robins Kaplan Insurance Insight June 2024
- First QuarterGeneric Launches
- January 3, 2024Navigating Class Actions After Papa John's Settlement Denial
- December 28, 2023Data Shows Most SEP Holders Send Pre-Suit Demand Letters - For Good Reason
- First QuarterANDA Approvals
- December 29, 2023Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
- Lawdragon:
In Conversation with Tara Sutton, Head of The Mass Tort Practice at Robins Kaplan - December 2023Advancement Proceedings: A Litigation Expense Your Client Might Not Have Anticipated
- December 2023Who Pays When You Fight Over a Trust?
- December 2023Can the Threat of Fees Discourage Unnecessary Fiduciary Disputes? Maybe...
- December 13, 2023Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
- December 7, 2023H. Lundbeck A/S v. Lupin Ltd.
- Fall 2023All Is Not Lost: Personal Jurisdiction in a Post-BMS World
- A New Era of Copyright Litigation in Hollywood
- E-Commerce Platform Liability for Trademark Infringement
- November 8, 2023Generative Artificial Intelligence, LLMs, And Fair Use After Warhol: The Copyright Office and Accountability
- November 7, 2023Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
- November 6, 2023Actelion Pharms. Ltd. v. Mylan Pharms. Inc.
- November 1, 2023Norwich Pharms., Inc. v. Becerra
